JP2015526469A - 癌に対する胎盤ワクチン接種療法 - Google Patents

癌に対する胎盤ワクチン接種療法 Download PDF

Info

Publication number
JP2015526469A
JP2015526469A JP2015528558A JP2015528558A JP2015526469A JP 2015526469 A JP2015526469 A JP 2015526469A JP 2015528558 A JP2015528558 A JP 2015528558A JP 2015528558 A JP2015528558 A JP 2015528558A JP 2015526469 A JP2015526469 A JP 2015526469A
Authority
JP
Japan
Prior art keywords
cells
cell
cancer
tumor
heterologous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015528558A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015526469A5 (enExample
Inventor
ボリス，マルコシアン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2015526469A publication Critical patent/JP2015526469A/ja
Publication of JP2015526469A5 publication Critical patent/JP2015526469A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55538—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2015528558A 2012-08-20 2013-08-19 癌に対する胎盤ワクチン接種療法 Pending JP2015526469A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261691187P 2012-08-20 2012-08-20
US61/691,187 2012-08-20
PCT/US2013/055632 WO2014031553A1 (en) 2012-08-20 2013-08-19 Placental vaccination therapy for cancer

Publications (2)

Publication Number Publication Date
JP2015526469A true JP2015526469A (ja) 2015-09-10
JP2015526469A5 JP2015526469A5 (enExample) 2016-10-06

Family

ID=50150330

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015528558A Pending JP2015526469A (ja) 2012-08-20 2013-08-19 癌に対する胎盤ワクチン接種療法

Country Status (4)

Country Link
US (2) US20150216957A1 (enExample)
EP (1) EP2925332A4 (enExample)
JP (1) JP2015526469A (enExample)
WO (1) WO2014031553A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021509122A (ja) * 2018-01-02 2021-03-18 クロリス・バイオサイエンシーズ・インコーポレイテッドＫｈｌｏｒｉｓ Ｂｉｏｓｃｉｅｎｃｅｓ， Ｉｎｃ． 癌のための予防および治療処置としてのｉｐｓｃベースのワクチン
WO2022191309A1 (ja) * 2021-03-12 2022-09-15 ドクタープロラボジャパン株式会社 プラセンタ抽出物の使用方法
JP7787510B2 (ja) 2021-03-12 2025-12-17 ドクタープロラボジャパン株式会社 プラセンタ抽出物の正常細胞増殖ヒト卵巣がん細胞増殖抑制用製剤の製造のための使用方法及び正常細胞増殖ヒト卵巣がん細胞増殖抑制用製剤の製造方法

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170080030A1 (en) * 2014-03-17 2017-03-23 University Of Virginia Patent Foundation Compositions and methods for treating retinopathy
WO2015168503A1 (en) * 2014-05-02 2015-11-05 Batu Biologics Compositions and means for induction of tumor immunity
US11026980B1 (en) 2018-02-26 2021-06-08 Triad Life Sciences, Inc. Flowable birth tissue composition and related methods
CN114585373B (zh) 2019-05-06 2025-07-22 艾克塞利瑞提德生物技术公司 前体调节性细胞滋养层细胞及其用途
CN115873790A (zh) * 2021-09-27 2023-03-31 金涌长生医学生物科技股份有限公司 一种蜕膜胎盘间充质干细胞及其在制备促进血管新生药物组合物中的用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009035527A (ja) * 2007-08-01 2009-02-19 Snowden Co Ltd 動物胎盤抽出物よりなるアンドロゲン受容体結合阻害剤
WO2012018145A2 (ja) * 2010-08-05 2012-02-09 株式会社日本生物製剤 Ｑｏｌ改善剤

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9107305D0 (en) 1991-04-08 1991-05-22 Unilever Plc Probiotic
US5843780A (en) 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
US6861053B1 (en) 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US6090622A (en) 1997-03-31 2000-07-18 The Johns Hopkins School Of Medicine Human embryonic pluripotent germ cells
ID29150A (id) 1999-01-15 2001-08-02 Entpr Ireland Cs Penggunaan lactobacillus salivarius
IT1318405B1 (it) * 2000-03-17 2003-08-25 Piermario Biava Composizione antitumorale costituita da una frazione di utero gravidoo di placenta di mammiferi.
TWI310686B (enExample) * 2002-10-18 2009-06-11 You Ru Qian
WO2008002005A1 (en) * 2006-06-27 2008-01-03 Choongangbiotech Co., Ltd. A method for preparing pig placental extract to use as a feed additive and use thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009035527A (ja) * 2007-08-01 2009-02-19 Snowden Co Ltd 動物胎盤抽出物よりなるアンドロゲン受容体結合阻害剤
WO2012018145A2 (ja) * 2010-08-05 2012-02-09 株式会社日本生物製剤 Ｑｏｌ改善剤

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
BAILLIERE'S CLINICAL OBSTETRICS AND GYNAECOLOGY, vol. 6, no. 3, JPN6018018851, 1992, pages 439 - 460, ISSN: 0003977909 *
BIOLOGY OF REPRODUCTION, vol. 66, JPN6018018850, 2002, pages 1853 - 1861, ISSN: 0003977908 *
CANCER IMMUNITY, vol. 7, JPN6018018854, 2007, pages 15 - 12, ISSN: 0003977912 *
CHINESE MEDICAL JOURNAL, vol. 124, no. 9, JPN6018018856, 2011, pages 1357 - 1361, ISSN: 0003977914 *
CYTOKINE, vol. 23, JPN6018018852, 2003, pages 119 - 125, ISSN: 0003977910 *
EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, vol. 110, JPN6018018853, 2003, pages 10 - 18, ISSN: 0003977911 *
INTERNATIONAL JOURNAL OF IMMUNOGENETICS, vol. 37, JPN6018018857, 2010, pages 329 - 336, ISSN: 0003977915 *
J. CLIN. ENDOCRINOL. METAB., vol. 87, JPN6018018849, 2002, pages 1353 - 1361, ISSN: 0003977907 *
J. TRANSLATIONAL MEDICINE, vol. 4(22), JPN6017021500, 2006, pages 1 - 9, ISSN: 0003977906 *
NEW薬理学（改訂第6版）, JPN6018018855, 5 April 2011 (2011-04-05), pages 182, ISSN: 0003977913 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021509122A (ja) * 2018-01-02 2021-03-18 クロリス・バイオサイエンシーズ・インコーポレイテッドＫｈｌｏｒｉｓ Ｂｉｏｓｃｉｅｎｃｅｓ， Ｉｎｃ． 癌のための予防および治療処置としてのｉｐｓｃベースのワクチン
JP2024026069A (ja) * 2018-01-02 2024-02-28 クロリス・バイオサイエンシーズ・インコーポレイテッド 癌のための予防および治療処置としてのｉｐｓｃベースのワクチン
WO2022191309A1 (ja) * 2021-03-12 2022-09-15 ドクタープロラボジャパン株式会社 プラセンタ抽出物の使用方法
JP2022140106A (ja) * 2021-03-12 2022-09-26 国立大学法人九州大学 プラセンタ抽出物の使用方法
JP7787510B2 (ja) 2021-03-12 2025-12-17 ドクタープロラボジャパン株式会社 プラセンタ抽出物の正常細胞増殖ヒト卵巣がん細胞増殖抑制用製剤の製造のための使用方法及び正常細胞増殖ヒト卵巣がん細胞増殖抑制用製剤の製造方法

Also Published As

Publication number Publication date
US20180125955A1 (en) 2018-05-10
WO2014031553A1 (en) 2014-02-27
US20150216957A1 (en) 2015-08-06
EP2925332A4 (en) 2016-12-21
EP2925332A1 (en) 2015-10-07

Similar Documents

Publication Publication Date Title
JP6920644B2 (ja) 幹細胞の免疫制御作用を調節する方法
Munoz‐Suano et al. Gimme shelter: the immune system during pregnancy
US20180125955A1 (en) Placental vaccination therapy for cancer
Laskarin et al. Antigen‐presenting cells and materno‐fetal tolerance: an emerging role for dendritic cells
CN110088623B (zh) 选择用于治疗免疫病症的高效干细胞的方法
KR102028340B1 (ko) 항원-특이적 t 세포의 증식 방법
EP1833496B1 (en) Treatment of stroke and other acute neural degenerative disorders using postpartum derived cells
EP2118267B1 (en) Novel methods for modulating inflammatory and/or immune responses
EP3052085B1 (en) Nanoparticle based artificial antigen presenting cell mediated activation of nkt cells
KR20140092298A (ko) 항 제3자 중심 기억 ｔ 세포, 이의 제조 방법, 및 이식 및 질환 치료에서의 이의 용도
JP6449148B2 (ja) 免疫抑制細胞作成方法、及び、免疫抑制細胞を含む組成物の使用方法
JP2023505102A (ja) ナチュラルキラー細胞を製造する方法およびその組成物
JP2013537187A (ja) 抗白血病／リンパ腫処置のための抗第三者セントラルメモリーｔ細胞の使用
KR20200020904A (ko) T-세포 증식 방법 및 용도
JP2024091728A (ja) Ｔ細胞の拡張及び活性化の方法
KR20230167397A (ko) 향상된 줄기 세포 유사 기억 t 세포 조작을 위한 물질 및 방법
WO2024103125A1 (en) Method of modifying cells
US9173908B2 (en) Methods for modulating immune responses
US20230149523A1 (en) Treatment of autoimmunity and transplant rejection through establishment and/or promotion of tolerogenic processes by fibroblast-mediated reprogramming of antigen presenting cells
US20250049919A1 (en) Prevention of Immunological Rejection Using Mesenchymal Stem Cells and Derivatives Thereof
Yang Immunomodulatory effects of interferon-alpha on T cell subsets in Behcet’s disease ex vivo, and the in vitro effects of treatment on healthy donor cells
Osada et al. Natural killer cell activation and dendritic cell-based vaccines
Joseph Costimulatory Effects of TLR1-TLR2 signaling in CD8+ T Cells

Legal Events

Date Code Title Description
RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20160816

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160817

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160817

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20160817

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170613

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170913

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171208

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180529

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180827

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20181024

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190219